Sarah Spiegel

Sarah Spiegel

Auto-generated profile, based on publicly available information

Sarah Spiegel

Department of Cellular, Molecular and Genetic Medicine and the Massey Comprehensive Cancer Center, Virginia Commonwealth University, Richmond, VA, 23298, USA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 June 2014 in Nature
Verified
Journal Article
Open access
PDF file
MMMichael Maceyka
Michael Maceyka
SSSarah Spiegel
Sarah Spiegel
Sphingolipids are ubiquitous building blocks of eukaryotic cell membranes. Progress in our understanding of sphingolipid metabolism, state-of-the-art sphingolipidomic approaches and animal models have generated a large body of evidence demonstrating that sphingolipid metabolites, particularly ceramide and sphingosine-1-phosphate, are signalling molecules that regulate a diverse range of cellular processes that are important in immunity, inflammation and inflammatory disorders. Recent insights into the molecular mechanisms of action of sphingolipid metabolites and new perspectives on their roles in regulating chronic inflammation have been reported. The knowledge gained in this emerging field will aid in the development of new therapeutic options for inflammatory disorders.

1 January 2012 in Trends in Cell Biology
Verified
Journal Article
Closed access
MMMichael Maceyka
Michael Maceyka
KHKB Harikumar
KB Harikumar
SMSheldon Milstien
Sheldon Milstien
SSSarah Spiegel
Sarah Spiegel

4 September 2009 in Science
Verified
Journal Article
Closed access
PDF file
NHNitai C. Hait
Nitai C. Hait
JAJeremy Allegood
Jeremy Allegood
MMMichael Maceyka
Michael Maceyka
GSGraham M. Strub
Graham M. Strub
KHKB Harikumar
KB Harikumar
SSSarah Spiegel
Sarah Spiegel
Epigenetic Signals: The lipid sphingosine-1-phosphate (S1P) is a signaling molecule that binds to receptors on the cell surface to initiate biochemical changes that control a range of biological processes from growth and survival to immune reactions. Hait et al. (p. 1254 ) report that S1P can also function by direct binding to the nuclear enzymes, histone deacetylases (HDACs) 1 and 2. The enzyme that generates S1P, sphingosine kinase 2 (ShpK2) is present in the nucleus in complexes with HDAC1 and HDAC2. Generation of S1P and its binding to HDACs inhibited deacetylation of histone. Such histone modification is an epigenetic mechanism that controls gene transcription. Thus, generation of S1P in the nucleus appears to be a signaling mechanism by which cells can control gene expression in response to various stimuli.

6 May 2011 in Nature Reviews Immunology
Verified
Journal Article
Closed access
PDF file
SSSarah Spiegel
Sarah Spiegel
SMSheldon Milstien
Sheldon Milstien

24 June 2010 in Nature
Verified
Journal Article
Open access
PDF file
SASergio E. Alvarez
Sergio E. Alvarez
KHKB Harikumar
KB Harikumar
NHNitai C. Hait
Nitai C. Hait
JAJeremy Allegood
Jeremy Allegood
GSGraham M. Strub
Graham M. Strub
SSSarah Spiegel
Sarah Spiegel
TRAF2 (tumour-necrosis factor receptor-associated factor 2), a component of the NF-κB activation pathway important in inflammatory, anti-apoptotic, and immune processes, is shown to be a target of sphingosine kinase 1, one of the isoenzymes that generates the pro-survival lipid mediator sphingosine-1-phosphate inside cells. In addition, sphingosine kinase 1 is revealed as the 'missing' cofactor for TRAF2 E3 ubiquitin ligase activity. These findings provide a mechanistic explanation for the numerous observations of the importance of SphK1 in inflammatory, anti-apoptotic and immune processes. Engagement of the tumour-necrosis factor (TNF) receptor results in the assembly of multi-component signalling complexes by adaptor proteins that include TNF receptor-associated factor 2 (TRAF2). Genetic evidence indicates that TRAF2 is needed for the polyubiquitination of receptor interacting protein 1 (RIP1), but direct evidence has been lacking. Here it is shown that the lipid sphingosine-1-phosphate is a co-factor needed for this ubiquitination activity of TRAF2. Tumour-necrosis factor (TNF) receptor-associated factor 2 (TRAF2) is a key component in NF-κB signalling triggered by TNF-α1,2. Genetic evidence indicates that TRAF2 is necessary for the polyubiquitination of receptor interacting protein 1 (RIP1)3 that then serves as a platform for recruitment and stimulation of IκB kinase, leading to activation of the transcription factor NF-κB. Although TRAF2 is a RING domain ubiquitin ligase, direct evidence that TRAF2 catalyses the ubiquitination of RIP1 is lacking. TRAF2 binds to sphingosine kinase 1 (SphK1)4, one of the isoenzymes that generates the pro-survival lipid mediator sphingosine-1-phosphate (S1P) inside cells. Here we show that SphK1 and the production of S1P is necessary for lysine-63-linked polyubiquitination of RIP1, phosphorylation of IκB kinase and IκBα, and IκBα degradation, leading to NF-κB activation. These responses were mediated by intracellular S1P independently of its cell surface G-protein-coupled receptors. S1P specifically binds to TRAF2 at the amino-terminal RING domain and stimulates its E3 ligase activity. S1P, but not dihydro-S1P, markedly increased recombinant TRAF2-catalysed lysine-63-linked, but not lysine-48-linked, polyubiquitination of RIP1 in vitro in the presence of the ubiquitin conjugating enzymes (E2) UbcH13 or UbcH5a. Our data show that TRAF2 is a novel intracellular target of S1P, and that S1P is the missing cofactor for TRAF2 E3 ubiquitin ligase activity, indicating a new paradigm for the regulation of lysine-63-linked polyubiquitination. These results also highlight the key role of SphK1 and its product S1P in TNF-α signalling and the canonical NF-κB activation pathway important in inflammatory, antiapoptotic and immune processes.

1 June 2008 in Pharmacological Reviews
Verified
Journal Article
Closed access
PDF file
Kazuaki TakabeKazuaki Takabe
Kazuaki Takabe
SPSteven W. Paugh
Steven W. Paugh
SMSheldon Milstien
Sheldon Milstien
SSSarah Spiegel
Sarah Spiegel
Sphingosine 1-phosphate (S1P) is a bioactive sphingolipid metabolite involved in many critical cellular processes including proliferation, survival, and migration, as well as angiogenesis and allergic responses. S1P levels inside cells are tightly regulated by the balance between its synthesis by sphingosine kinases and degradation. S1P is interconvertible with ceramide, which is a critical mediator of apoptosis. It has been postulated that the ratio between S1P and ceramide determines cell fate. Activation of sphingosine kinase by a variety of agonists increases intracellular S1P, which in turn can function intracellularly as a second messenger or be secreted out of the cell and act extracellularly by binding to and signaling through S1P receptors in autocrine and/or paracrine manners. Recent studies suggest that this “inside-out” signaling by S1P may play a role in many human diseases, including cancer, atherosclerosis, inflammation, and autoimmune disorders such as multiple sclerosis. In this review we summarize metabolism of S1P, mechanisms of sphingosine kinase activation, and S1P receptors and their downstream signaling pathways and examine relationships to multiple disease processes. In particular, we describe recent preclinical and clinical trials of therapies targeting S1P signaling, including 2-amino-2-propane-1,3-diol hydrochloride (FTY720, fingolimod), S1P receptor agonists, sphingosine kinase inhibitors, and anti-S1P monoclonal antibody.